Connection
Ty Kiser to Thrombocytopenia
This is a "connection" page, showing publications Ty Kiser has written about Thrombocytopenia.
|
|
Connection Strength |
|
|
|
|
|
2.025 |
|
|
|
-
Golightly LK, Simendinger BA, Kiser TH. Cancer-associated thromboembolism: antithrombotic management of hospitalized patients. J Thromb Thrombolysis. 2020 Jan; 49(1):59-66.
Score: 0.606
-
Kiser TH, Mann AM, Trujillo TC, Hassell KL. Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia. Am J Hematol. 2011 Mar; 86(3):267-72.
Score: 0.328
-
Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2008 Sep; 28(9):1115-24.
Score: 0.276
-
Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy. 2006 Apr; 26(4):452-60.
Score: 0.234
-
Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy. 2005 Dec; 25(12):1736-45.
Score: 0.228
-
Van Matre ET, Reynolds PM, MacLaren R, Mueller SW, Wright GC, Moss M, Burnham EL, Ho PM, Vandivier RW, Kiser TH. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. J Thromb Haemost. 2018 12; 16(12):2492-2500.
Score: 0.140
-
Babilonia KM, Golightly LK, Gutman JA, Hassell KL, Kaiser JN, Kiser TH, Klem PM, Trujillo TC. Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization. Clin Appl Thromb Hemost. 2014 Nov; 20(8):799-806.
Score: 0.104
-
Mueller SW, MacLaren R, Fish DN, Kiser TH. Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy. Ann Pharmacother. 2009 Jul; 43(7):1360-5.
Score: 0.073
-
Reynolds PM, Van Matre ET, Wright GC, McQueen RB, Burnham EL, Ho PJM, Moss M, Vandivier RW, Kiser TH. Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically Ill Patient. Pharmacotherapy. 2019 03; 39(3):232-241.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|